NIAID-Led Study of mRNA Vaccine Supports Advance to Phase 3 Human Trials
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.
The candidate vaccine, mRNA-1273, was co-developed by scientists at the NIAID Vaccine Research Center and at Moderna, Inc., Cambridge, Massachusetts. The animal study results published online today in the New England Journal of Medicine complement recently reported interim results from an NIAID-sponsored Phase 1 clinical trial of mRNA-1273. The candidate mRNA-1273 vaccine is manufactured by Moderna.
In this study, three groups of eight rhesus macaques received two injections of 10 or 100 micrograms (µg) of mRNA-1273 or a placebo. Injections were spaced 28 days apart. Vaccinated macaques produced high levels of neutralizing antibodies directed at the surface spike protein used by SARS-CoV-2 to attach to and enter cells. Notably, say the investigators, animals receiving the 10-µg or 100-µg dose vaccine candidate produced neutralizing antibodies in the blood at levels well above those found in people who recovered from COVID-19.
The experimental vaccine also induced Th1 T-cell responses but not Th2 responses. Induction of Th2 responses has been associated with a phenomenon called vaccine-associated enhancement of respiratory disease (VAERD). Vaccine-induced Th1 responses have not been associated with VAERD for other respiratory diseases. In addition, the experimental vaccine induced T follicular helper T-cell responses that may have contributed to the robust antibody response.
Four weeks after the second injection, all the macaques were exposed to SARS-CoV-2 via both the nose and the lungs. Remarkably, after two days, no replicating virus was detectable in the lungs of seven out of eight of the macaques in both vaccinated groups, while all eight placebo-injected animals continued to have replicating virus in the lung. Moreover, none of the eight macaques vaccinated with 100 µg of mRNA-1273 had detectable virus in their noses two days after virus exposure. This is the first time an experimental COVID-19 vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note. A COVID-19 vaccine that reduces viral replication in the lungs would limit disease in the individual, while reducing shedding in the upper airway would potentially lessen transmission of SARS-CoV-2 and consequently reduce the spread of disease, they add.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Full approval of Pfizer vaccine comes as vaccinations slowly increase in Hampton Roadson August 23, 2021 at 3:34 pm
Pfizer has said that its vaccine is 90% effective in protecting a fully vaccinated person from getting COVID-19.
- Pfizer COVID vaccine goes by new name after FDA approvalon August 23, 2021 at 3:28 pm
With full approval also comes a new name for the first COVID-19 vaccine to cross the FDA finish line. The Pfizer vaccine has gone by Pfizer, Pfizer-BioNTech, and BNT162b2 in the science community. It ...
- How a vial of Pfizer COVID-19 vaccine travels from a lab in Missouri to an arm in Bangladeshon August 23, 2021 at 2:58 pm
A vaccine dose’s 60-day journey to distribution starts with raw ingredients in a Pfizer factory in Chesterfield, Missouri.
- mRNA COVID-19 Vaccine Effectiveness Lower During Delta Strain Eraon August 23, 2021 at 10:46 am
(HealthDay News) — mRNA COVID-19 vaccines provide protection against infection among nursing home residents, but the vaccine effectiveness was lower after the delta variant became the predominant ...
- FDA approves COVID-19 mRNA vaccine that uses fundamental Penn technologyon August 23, 2021 at 9:48 am
The U.S. Food and Drug Administration has given the first full approval to a COVID-19 mRNA vaccine, which uses modified mRNA technology invented and developed by scientists in the Perelman School of ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?on August 20, 2021 at 11:41 am
Moderna’s MRNA mRNA-based COVID-19 vaccine, mRNA-1273 is being investigated by the FDA and the U.S. Centers for Disease Control and Prevention (CDC) for higher risk of myocarditis, a rare condition of ...
- Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?on August 20, 2021 at 8:18 am
COVID-19 vaccine is being probed for higher risk of heart inflammation compared to Pfizer's vaccine, per a Washington Post article.
- Moderna (MRNA) Gets EUA for Third Dose of COVID-19 Vaccineon August 17, 2021 at 7:28 am
MRNA announced that the FDA has expanded the emergency use authorization (“EUA”) for its mRNA-based COVID-19 vaccine, mRNA-1273, to include a third dose for certain immunocompromised individuals. The ...
- Primate study shows benefit of mRNA vaccine booster shot against SARS-CoV-2 variantson August 15, 2021 at 10:03 pm
In a recent bioRxiv* preprint research paper, a large group of US scientists demonstrate how a booster dose of the mRNA-1273 vaccine can substantially improve both the potency and range of ...
- Both mRNA vaccines protect against symptomatic disease with SARS-CoV-2 Delta varianton August 15, 2021 at 4:28 pm
A new study demonstrates that the two mRNA vaccines have widely varying efficacies against the SARS-CoV-2 Delta variant.